



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 8.01. Other Events.

On July 25, 2018, CorMedix issued a press release announcing positive results for its Phase 3 clinical trial for Neutrolin®, based on the recommendation by an independent Data Safety Monitoring Board.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press release dated July 25, 2018



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 25, 2018    CORMEDIX INC.

/s/ Robert W. Cook  
Name: Robert W. Cook  
Title: Chief Financial Officer